- Stocks
- Pharma & Healthcare
- Sakar Healthcare
Sakar Healthcare share price
NSE: SAKARPharma & HealthcareDrug Manufacturers - Specialty & Generic
Sakar Healthcare at a glance
Sakar Healthcare (NSE: SAKAR) closed at ₹923.90 on 22 Oct 2026, up 2.66% on the day. With a market capitalisation of ₹2,056 Cr, it ranks 1135th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 67.6× trailing earnings, against a return on equity of 9.4% in FY26. Over the past year the share price has risen 156.4%. Its 52-week range is ₹352.00 (27 Oct 2025) to ₹1,229.85 (23 Sep 2026); the last close is 24.9% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹73 Cr (+38.4% year on year) and net profit ₹10 Cr (+120.1%), on a consolidated basis. Promoters held 52.52% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹2,056 CrRank 1135 on NSE
- P/E (trailing)
- 67.6×
- Price to book
- 3.42×FY26
- EPS (TTM)
- ₹16.20to Q1 FY27
- ROE
- 9.4%FY26
- ROCE
- 12.8%FY26
- Debt to equity
- 0.17FY26
- Net profit margin
- 12.1%FY26
- Book value / share
- ₹145.82FY26
- 52-week high
- ₹1,229.8523 Sep 2026
- 52-week low
- ₹352.0027 Oct 2025
- 1-year return
- +156.4%
- RSI (14-day)
- 39.5
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +2.66% | −9.3% | −20.6% | +11.2% | +156.4% |
Sakar Healthcare quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹43 Cr | ₹43 Cr | ₹50 Cr | ₹53 Cr | ₹58 Cr | ₹70 Cr | ₹71 Cr | ₹73 Cr |
| Revenue YoY | +25.5% | +16.6% | +16.7% | +28.2% | +34.5% | +62.0% | +41.5% | +38.4% |
| Net profit | ₹5 Cr | ₹5 Cr | ₹6 Cr | ₹5 Cr | ₹5 Cr | ₹10 Cr | ₹11 Cr | ₹10 Cr |
| Net profit YoY | +31.9% | +118.8% | +84.6% | +93.8% | −5.4% | +126.3% | +91.3% | +120.1% |
| Net margin | 11.2% | 10.4% | 11.5% | 8.9% | 7.9% | 14.6% | 15.5% | 14.1% |
| EPS | ₹2.17 | ₹2.08 | ₹2.66 | ₹2.11 | ₹2.03 | ₹4.59 | ₹4.96 | ₹4.62 |
Sakar Healthcare financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹95 Cr | ₹128 Cr | ₹133 Cr | ₹153 Cr | ₹178 Cr | — |
| Operating profit | ₹13 Cr | ₹19 Cr | ₹17 Cr | ₹16 Cr | ₹22 Cr | — |
| Net profit | ₹11 Cr | ₹15 Cr | ₹13 Cr | ₹12 Cr | ₹18 Cr | — |
| EPS (₹) | ₹7.00 | ₹9.00 | ₹7.00 | ₹6.00 | ₹8.00 | — |
| Cash from operations | ₹15 Cr | ₹36 Cr | ₹33 Cr | ₹24 Cr | ₹34 Cr | — |
| Total debt | ₹38 Cr | ₹85 Cr | ₹98 Cr | ₹55 Cr | ₹54 Cr | ₹31 Cr |
| Shareholders' equity | ₹98 Cr | ₹127 Cr | ₹173 Cr | ₹262 Cr | ₹285 Cr | ₹324 Cr |
Sakar Healthcare shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 53.58% | 52.86% | 52.86% | 52.86% | 52.86% | 52.52% |
| Foreign institutions | 13.61% | 13.41% | 13.31% | 13.05% | 12.94% | 12.13% |
| Domestic institutions | 10.97% | 11.25% | 11.43% | 11.36% | 11.32% | 11.37% |
| Non-institutions | 21.85% | 22.48% | 22.41% | 22.73% | 22.87% | 23.98% |
Sakar Healthcare vs peers
The listed Pharma & Healthcare companies nearest to Sakar Healthcare by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| MEDIASSISTMedi Assist Healthcare Services | ₹291.75 | −0.61% | −46.7% | ₹2,179 Cr | 24.1 | — |
| SYNCOMFSyncom Formulations (India) | ₹22.83 | +3.21% | +38.8% | ₹2,146 Cr | 28.2 | — |
| INDOCOIndoco Remedies | ₹230.55 | +0.74% | −21.9% | ₹2,128 Cr | — | — |
| PANACEABIOPanacea Biotec | ₹335.85 | −1.22% | −24.2% | ₹2,057 Cr | — | — |
| SAKARSakar Healthcare | ₹923.90 | +2.66% | +156.4% | ₹2,056 Cr | 67.6 | — |
| SAIPARENTSai Parenterals | ₹461.90 | −1.31% | — | ₹2,041 Cr | 103.6 | — |
| BETABeta Drugs | ₹1,773.00 | +5.60% | +3.3% | ₹1,966 Cr | 43.4 | — |
Ask anything about Sakar Healthcare
Pivot answers on the live chart with evidence you can check, and tests strategies against SAKAR's own history. Try: “Why has SAKAR moved over the last three months?” · “Backtest a 50-day moving-average crossover on SAKAR over five years” · “Compare SAKAR with MEDIASSIST on margins and valuation”
Frequently asked questions about Sakar Healthcare
What is the share price of Sakar Healthcare today?
Sakar Healthcare (NSE: SAKAR) last closed at ₹923.90 on 22 Oct 2026. Its 52-week high is ₹1,229.85 and its 52-week low is ₹352.00.
What is the market cap of Sakar Healthcare?
Sakar Healthcare's market capitalisation is ₹2,056 Cr (₹2,056 Cr) at the 22 Oct 2026 close, ranking 1135th among the NSE companies Pivot tracks.
What is the P/E ratio of Sakar Healthcare?
Sakar Healthcare trades at a trailing P/E of 67.6. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 43.4.
What is the ROE and ROCE of Sakar Healthcare?
Return on equity was 9.4% in FY26 and return on capital employed was 12.8% in FY26 (consolidated figures).
Is Sakar Healthcare a debt-free company?
No. Sakar Healthcare's debt-to-equity ratio was 0.17 in FY26, with total debt of ₹31 Cr.
What were Sakar Healthcare's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Sakar Healthcare reported revenue of ₹73 Cr, +38.4% year on year, and net profit of ₹10 Cr, +120.1% year on year.
How has Sakar Healthcare stock performed over the last year?
Sakar Healthcare's share price has risen 156.4% over the past year, +11.2% over three months and −20.6% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Sakar Healthcare?
As of 30 Jun 2026: promoters 52.52%, foreign institutions 12.13%, domestic institutions 11.37%, non-institutions 23.98%.
Who are Sakar Healthcare's competitors?
The listed Pharma & Healthcare companies closest to Sakar Healthcare by market cap are Medi Assist Healthcare Services, Syncom Formulations (India), Indoco Remedies, Panacea Biotec, Sai Parenterals and Beta Drugs.
Is Sakar Healthcare a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Sakar Healthcare's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SAKAR against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text